WGS logo

GeneDx Holdings Corp. (WGS)

$47.29

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on WGS

Market cap

$1.42B

EPS

-3.76

P/E ratio

--

Price to sales

4.42

Dividend yield

--

Beta

2.017503

Price on WGS

Previous close

$51.02

Today's open

$51.43

Day's range

$44.24 - $51.68

52 week range

$32.21 - $170.87

Profile about WGS

CEO

Katherine Stueland

Employees

1300

Headquarters

Stamford, CT

Exchange

Nasdaq Global Select

Shares outstanding

29972493

Issue type

Common Stock

WGS industries and sectors

Healthcare

Medical Diagnostics & Screening

News on WGS

GeneDx Announces Leadership Transition

GAITHERSBURG, Md.--(BUSINESS WIRE)--Everett Cunningham, veteran diagnostics and commercial leader, appointed Chief Executive Officer of GeneDx to lead next phase of growth.

news source

Business Wire • 7 hours ago

news preview

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.

news source

Business Wire • Nov 11, 2026

news preview

Why GeneDx Holdings Stock Just Dropped 16.6%

GeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations. Sales rose 5% to $123.1 million, in line with estimates, but the 32,134 exome and genome results were up 25% against the 29.2% or more the company had promised.

news source

The Motley Fool • Nov 10, 2026

news preview

GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript

GeneDx Holdings Corp. ( WGS ) Q3 2026 Earnings Call November 9, 2026 4:30 PM EST Company Participants Sabrina Dunbar - Director of Investor Relations & Communications Katherine Stueland - CEO & Director Mark Gardner - President Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division David Westenberg - Piper Sandler & Co., Research Division Tycho Peterson - Jefferies LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2026 Earnings Conference Call.

news source

Seeking Alpha • Nov 10, 2026

news preview

GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients.

news source

Business Wire • Nov 10, 2026

news preview

4 Post-Earnings Losers Drawing Unusual Options Volume

Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and Digital Turbine Inc (NASDAQ:APPS) all suffering double-digit losses today.

news source

Schaeffers Research • Nov 10, 2026

news preview

GeneDx Q3 Earnings Call Highlights

GeneDx NASDAQ: WGS reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its expectations for test volume growth.

news source

MarketBeat • Nov 10, 2026

news preview

GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability

GeneDx Holdings is transitioning to sustained profitability, with strong revenue growth expected through 2027. WGS beat revenue estimates for Q3 but fell short on EPS estimates. Key strategies include optimizing reimbursement rates, operational efficiencies, and leveraging AI to enhance billing and payment reliability.

news source

Seeking Alpha • Nov 10, 2026

news preview

GeneDx Reports Third Quarter 2026 Financial Results

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2026.

news source

Business Wire • Nov 9, 2026

news preview

GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.49 per share a year ago.

news source

Zacks Investment Research • Nov 10, 2026

news preview

¹ Disclosures

Get started with M1

Invest in GeneDx Holdings Corp.

Open an M1 investment account to buy and sell GeneDx Holdings Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in WGS on M1